News | December 21, 2025
Alvotech, Teva secure US settlement with Regeneron for Eylea biosimilar launch
Under the agreement, AVT06 is licensed to enter the US market in the fourth quarter of 2026
Under the agreement, AVT06 is licensed to enter the US market in the fourth quarter of 2026
Takeda said zasocitinib was generally well tolerated, with a safety profile consistent with earlier studies
USFDA determines Sun Pharma's Baska facility inspection classification as OAI
The upcoming trials will evaluate both active and chronic TED in randomized, double-blind, placebo-controlled studies
Imsidolimab, an IgG4 IL-36 receptor antagonist, works by inhibiting IL-36 receptor signaling, directly addressing the deficiency in the IL-36RA regulator common in GPP patients
If approved, CUTX-101 will be the first and only FDA approved treatment available for Menkes disease
WINREVAIR is currently the first and only activin signalling inhibitor approved for PAH across all 27 EU member states
The approval of Augmentin XR, granted to USAntibiotics, directly supports the CNPV program’s goals
This approval confirms the facility's compliance with FDA quality standards and regulatory requirements
Alport Syndrome is caused by genetic mutations affecting type IV collagen in the kidneys, ears, and eyes
Subscribe To Our Newsletter & Stay Updated
